Company news

CStone Pharmaceuticals news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Voluntary announcement - cstone announces major clinical validation milestone for CS2009 at esmo 2026: data from more than 300 patients support mechanism, safety and broad antitumor activity

October 25, 2026

Monthly return of equity issuer on movements in securities for the month ended 30 September 2026

October 7, 2026

Interim report 2026

September 28, 2026

Voluntary announcement - increase in shareholding by CEO and executive director dr. jianxin yang by 496,000 shares, with accumulated purchase totaling 14,210,500 shares

September 24, 2026

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

August 27, 2026

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

June 25, 2026

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

June 11, 2026

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

May 31, 2026

CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)

April 19, 2026

CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

March 26, 2026

CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC

February 22, 2026

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 to Advance into Phase II Clinical Trial

February 16, 2026

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

February 15, 2026

ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut

November 6, 2025

ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

October 19, 2025

CStone Announces 2025 Interim Results, Pipeline Acceleration and Value Potential Unlocked

August 15, 2025

CStone Signs Exclusive License Agreement with Istituto Gentili for Sugemalimab in Western Europe and the UK

July 8, 2025

CStone Announces Clinical Progress Update on CS2009

July 7, 2025

CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR

May 5, 2025

CStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR

May 4, 2025

CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress

March 27, 2025

CStone to Showcase Five Latest Research Achievements at AACR 2025

March 25, 2025

CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer

March 23, 2025

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

March 5, 2025

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody

March 3, 2025

CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab in JAMA

February 26, 2025

CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA

February 24, 2025

CStone Announces Inclusion of Cejemly as a First-Line Combination Therapy for NSCLC in ESMO Guideline

February 10, 2025

CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody

December 23, 2024

CStone Pharmaceuticals Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer in the UK

November 1, 2024

Decks

The 5 newest of 23 decks. Every deck is listed under its year.